Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?

Title

Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?

Creator

Watkins Richard R; Deresinski Stan

Publisher

Expert review of anti-infective therapy

Date

2015
2015-04

Description

Carbapenem-resistant Klebsiella pneumoniae causes serious nosocomial infections and therapeutic options are limited. There is increasing evidence suggesting that combination antibiotic therapy is more effective than monotherapy and leads to better outcomes. However, questions remain about which regimen is optimal and how to balance the potential benefits of combination therapy versus the risks and possible complications (e.g., toxicity, increased costs, Clostridium difficile infection). Well-designed randomized clinical trials are needed to clarify these issues.

Subject

Humans; Randomized Controlled Trials as Topic; Anti-Bacterial Agents/*therapeutic use; beta-Lactam Resistance/genetics; carbapenem-resistant Klebsiella pneumoniae; Carbapenems/*therapeutic use; combination antibiotic therapy; Klebsiella Infections/*drug therapy/microbiology; Klebsiella pneumoniae/*drug effects/genetics/pathogenicity; Drug Therapy; Combination/*statistics & numerical data

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

405–407

Issue

4

Volume

13

Citation

Watkins Richard R; Deresinski Stan, “Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?,” NEOMED Bibliography Database, accessed June 13, 2021, https://neomed.omeka.net/items/show/5018.

Social Bookmarking